Executives want 'skin in the game' despite signs of stock market cooldown

no paywall

2025 was a breakout year for China’s biopharma industry. Out-licensing deals, in which a Chinese biotech company grants another drugmaker the rights to develop, produce and sell its drug candidates, hit a record $135.7 billion, according to data provider Pharmcube. That was nearly triple the value in 2024.